1Kim ES,Hirsh V,Mok T. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST):a randomised phase Ⅲ trial[J].The Lancet,2008,(9652):1809-1818.
2Shepherd FA,Dancey J,Ramlau R. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy[J].Journal of Clinical Oncology,2000,(10):2095-2103.
3Fossella F,Devore R,Kerr RN. Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.The TAX 320 Non-Small Cell Lung Cancer Study Group[J].Journal of Clinical Oncology,2000,(12):2354-2362.
4Hanna N,Shepherd FA,Fossella FV. Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy[J].Journal of Clinical Oncology,2004,(09):1589-1597.
5Shepherd FA,Rodrigues PJ,Ciuleanu T. Erlotinib in previously treated non-small-cell lung cancer[J].New England Journal of Medicine,2005,(02):123-132.
6Ciuleanu T,Stelmakh L,Cicenas S. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced,non-small-cell lung cancer with poor prognosis (TITAN):a randomised multi-centre,open-label,phase 3 study[J].Lancet Oncology,2012,(03):300-308.
7Lee DH,Park K,Kim JH. Randomized phase Ⅲ trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy[J].Clinical Cancer Research,2010,(04):1307-1314.
9Kim ST,Uhm JE,Lee J. Randomized phase Ⅱ study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy[J].Lung Cancer,2012,(01):82-88.
10Douillard JY,Shepherd FA,Hirsh V. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer:data from the randomized phase Ⅲ INTEREST trial[J].Journal of Clinical Oncology,2010,(05):744-752.doi:10.1200/JCO.2009.24.3030.
